Taken together, these results suggest that cabozantinib treatment drastically increased tumor-associated hypoxic stress, and tumor growth inhibition likely occurred independent of MET pathway inhibition in the LuCaP 93 PDX model. The gene discussed is MET; the disease is neoplasm.